Andean Precious Metals Corp. (APM)

Overview

Aptorum Group Limited is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products aimed at treating a range of diseases, primarily in oncology and infectious diseases. The company, incorporated in 2010 and headquartered in London, United Kingdom, operates through its subsidiaries under two segments: Therapeutics and Non-Therapeutics. Originally known as APTUS Holdings Limited, it rebranded to Aptorum Group Limited in October 2017. Aptorum Group's engagement in therapeutic and diagnostic projects spans across various other disease areas including neurology, gastroenterology, and metabolic disorders, leveraging on its systematic screening of approved drug molecules and microbiome-based research platforms.

Products and Services

• SACT-1

  Designed for the treatment of neuroblastoma and other cancer types, SACT-1 represents the company's foray into oncology therapeutics.

• SACT-COV19

  This product is in development for addressing the coronavirus disease, showcasing Aptorum Group's response to infectious disease outbreaks.

• ALS-4

  ALS-4 is aimed at treating bacterial infections caused by Staphylococcus aureus, including methicillin-resistant strains (MRSA), highlighting the company's commitment to combating antibiotic-resistant bacteria.

• ALS-1

  Targeted at viral infections, ALS-1 is being developed to treat influenza virus A infections, reinforcing the company's focus on infectious diseases.

• ALS-2/3

  These two products are being developed for the treatment of Gram-positive bacterial infections, expanding the company's antibacterial portfolio.

• RPIDD

  A pathogen molecular diagnostic project, RPIDD stands as a testament to Aptorum Group's dedication to advancing diagnostic capabilities alongside therapeutic solutions.

• NativusWell DOI (NLS-2)

  A dietary supplement, NLS-2 underlines Aptorum Group’s interests in non-therapeutic offerings aimed at general wellness and metabolic disease prevention.

• NLS-1

  For the treatment of endometriosis, NLS-1 underscores the company's attention to women's health and reproductive diseases.

• DLS-1+2

  These products are geared towards treating non-small cell lung cancer (NSCLC) with specific mutations, highlighting Aptorum Group’s investment in targeted cancer therapies.

• DLS-3

  An autoimmune small molecule, indicating the company's exploration into treatments for autoimmune disorders.

• CLS-1

  Focused on the treatment of obesity, CLS-1 represents Aptorum Group’s venture into metabolic disorders beyond diabetes and lipid anomalies.